$RSLS
ReShape Lifesciences Inc. Stock $rsls

$rsls Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000142757020000062 Filed on November 06, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2020 Q1
Revenue	$61.00K	$3.602M	$800.0K
YoY Change	-98.49%	981.68%	-55.56%
Cost Of Revenue	-$1.000K	$1.321M	$541.0K
YoY Change	-100.05%	220.63%	-56.09%
Gross Profit	$62.00K	$2.281M	$239.0K
YoY Change	-97.07%	-2987.34%	-55.99%
Gross Profit Margin	101.64%	63.33%	29.88%
Selling, General & Admin	$1.230M	$1.160M	$3.893M
YoY Change	-72.64%	-53.39%	-37.25%
% of Gross Profit	1983.87%	50.85%	1628.87%
Research & Development	$160.0K	$859.0K	$1.257M
YoY Change	-35.22%	-26.83%	-48.46%
% of Gross Profit	258.06%	37.66%	525.94%
Depreciation & Amortization	$80.00K	$73.00K	$103.0K
YoY Change	-81.0%	-82.7%	-76.21%
% of Gross Profit	129.03%	3.2%	43.1%
Operating Expenses	$1.387M	$4.453M	$5.150M
YoY Change	-70.76%	21.57%	-40.41%
Operating Profit	-$1.325M	-$2.172M	-$4.911M
YoY Change	-49.58%	-41.96%	-39.37%
Interest Expense	$0.00	-$739.0K	$35.00K
YoY Change	-100.0%	-2097.3%	-118.42%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	-$385.0K
YoY Change	-100.0%	-100.0%
Pretax Income	-$1.325M	-$5.218M	-$5.261M
YoY Change	-94.78%	-81.85%	17.54%
Income Tax		-$39.00K
% Of Pretax Income
Net Earnings	-$1.325M	-$5.179M	-$5.261M
YoY Change	-94.71%	39.75%	-36.54%
Net Earnings / Revenue	-2172.13%	-143.78%	-657.63%
Basic Earnings Per Share		-$1.32
Diluted Earnings Per Share	-$511.5K	-$1.32	-$2.043M
COMMON SHARES
Basic Shares Outstanding	7.771M shares	3.928M	7.732M shares
Diluted Shares Outstanding		3.928M

Balance Sheet

Concept	2020 Q4	2020 Q3	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.905M	$5.514M	$8.915M
YoY Change	33.05%	-28.55%	387.69%
Cash & Equivalents	$2.957M	$5.514M	$8.900M
Short-Term Investments
Other Short-Term Assets	$159.0K	$3.517M	$4.786M
YoY Change	-91.88%	414.93%	210.98%
Inventory	$2.244M	$0.00	$1.408M
Prepaid Expenses		$186.0K	$1.535M
Receivables	$0.00	$0.00	$461.0K
Other Receivables	$3.150M	$3.150M	$3.150M
Total Short-Term Assets	$8.944M	$9.031M	$15.57M
YoY Change	-50.95%	-59.59%	-47.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$584.0K	$982.0K	$2.159M
YoY Change	-45.98%	-12.09%	76.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$46.00K	$1.303M
YoY Change		122.35%
Total Long-Term Assets	$28.12M	$2.931M	$3.659M
YoY Change	1202.92%	26.99%	48.98%
TOTAL ASSETS
Total Short-Term Assets	$8.944M	$9.031M	$15.57M
Total Long-Term Assets	$28.12M	$2.931M	$3.659M
Total Assets	$37.06M	$11.96M	$19.23M
YoY Change	81.73%	-51.49%	-40.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.655M	$656.0K	$1.070M
YoY Change	464.04%	-10.38%	2.49%
Accrued Expenses	$3.630M	$4.333M	$5.656M
YoY Change	-11.72%	-26.26%	1412.3%
Deferred Revenue		$61.00K	$462.0K
YoY Change		-78.45%	24.86%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.609M
YoY Change
Total Short-Term Liabilities	$11.61M	$5.050M	$7.188M
YoY Change	191.8%	29.32%	-71.28%
LONG-TERM LIABILITIES
Long-Term Debt	$9.168M	$430.0K	$0.00
YoY Change		-90.61%
Other Long-Term Liabilities	$476.0K	$7.000K	$969.0K
YoY Change
Total Long-Term Liabilities	$9.168M	$990.0K	$969.0K
YoY Change	1516.93%	44.1%	18.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.61M	$5.050M	$7.188M
Total Long-Term Liabilities	$9.168M	$990.0K	$969.0K
Total Liabilities	$22.57M	$6.040M	$8.157M
YoY Change	396.76%	31.53%	-68.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$514.8M	-$183.4M	-$177.7M
YoY Change	198.57%	9.49%	13.18%
Common Stock	$4.000K	$189.4M	$188.8M
YoY Change	-100.0%	0.95%	15.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.49M	$17.08M	$21.57M
YoY Change
Total Liabilities & Shareholders Equity	$37.06M	$11.96M	$19.23M
YoY Change	81.73%	-51.49%	-40.59%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2020 Q1
OPERATING ACTIVITIES
Net Income	-$1.325M	-$5.179M	-$5.261M
YoY Change	-94.71%	39.75%	-36.54%
Depreciation, Depletion And Amortization	$80.00K	$73.00K	$103.0K
YoY Change	-81.0%	-82.7%	-76.21%
Cash From Operating Activities	-$1.555M	-$1.290M	-$4.814M
YoY Change	17.71%	-69.86%	-50.07%
INVESTING ACTIVITIES
Capital Expenditures	-$54.00K	$0.00	$326.0K
YoY Change	285.71%		1615.79%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$54.00K	$0.00	-$326.0K
YoY Change	-97.32%		-112.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-1.555M	-1.290M	-$4.814M
Cash From Investing Activities	-54.00K	0.000	-$326.0K
Cash From Financing Activities	0.000	0.000	$0.00
Net Change In Cash	-1.609M	-1.290M	-$5.140M
YoY Change	-66.0%	-138.27%	-246.98%
FREE CASH FLOW
Cash From Operating Activities	-$1.555M	-$1.290M	-$4.814M
Capital Expenditures	-$54.00K	$0.00	$326.0K
Free Cash Flow	-$1.501M	-$1.290M	-$5.140M
YoY Change	14.84%	-69.86%	-46.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001427570
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7770698	shares
	obln	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	378000	USD
CY2020Q3	obln	Lessee Liability Payments Due LesseeLiabilityPaymentsDue	1414000	USD
CY2020Q3	obln	Lessee Liability Undiscounted Excess Amount LesseeLiabilityUndiscountedExcessAmount	278000	USD
	obln	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	301000	USD
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	OBALON THERAPEUTICS INC
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	obln	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	0	USD
CY2020Q3	obln	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	64000	USD
CY2019Q4	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	198000	USD
CY2020Q3	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	0	USD
CY2019Q4	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	412000	USD
CY2020Q3	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	111000	USD
CY2019Q4	obln	Accrued Settlement Liability Current AccruedSettlementLiabilityCurrent	0	USD
CY2020Q3	obln	Accrued Settlement Liability Current AccruedSettlementLiabilityCurrent	3150000	USD
CY2020Q3	obln	Accrued Settlement Liability Current AccruedSettlementLiabilityCurrent	3150000	USD
	obln	Fair Value Adjustmentof Cash Settled Options FairValueAdjustmentofCashSettledOptions	0	USD
	obln	Fair Value Adjustmentof Cash Settled Options FairValueAdjustmentofCashSettledOptions	7000	USD
	obln	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-248000	USD
	obln	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-293000	USD
	obln	Issuanceof Warrantsfor Purchaseof Common Stock IssuanceofWarrantsforPurchaseofCommonStock	0	USD
	obln	Issuanceof Warrantsfor Purchaseof Common Stock IssuanceofWarrantsforPurchaseofCommonStock	45000	USD
CY2020Q3	obln	Lease Liability LeaseLiability	1136000	USD
CY2019Q4	obln	Lease Liability Current LeaseLiabilityCurrent	561000	USD
CY2020Q3	obln	Lease Liability Current LeaseLiabilityCurrent	583000	USD
CY2019Q4	obln	Lease Liability Noncurrent LeaseLiabilityNoncurrent	567000	USD
CY2020Q3	obln	Lease Liability Noncurrent LeaseLiabilityNoncurrent	553000	USD
CY2019Q4	obln	Manufacturing Use Assets Current ManufacturingUseAssetsCurrent	0	USD
CY2020Q3	obln	Manufacturing Use Assets Current ManufacturingUseAssetsCurrent	166000	USD
	obln	Proceedsfrom Issuanceof Common Stockand Exerciseof Prefunded Warrants Netof Issuance Costs ProceedsfromIssuanceofCommonStockandExerciseofPrefundedWarrantsNetofIssuanceCosts	15014000	USD
	obln	Proceedsfrom Issuanceof Common Stockand Exerciseof Prefunded Warrants Netof Issuance Costs ProceedsfromIssuanceofCommonStockandExerciseofPrefundedWarrantsNetofIssuanceCosts	0	USD
CY2020Q3	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Aggregate Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingAggregateIntrinsicValue	0	USD
CY2020Q3	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Number SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingNumber	0	shares
CY2020Q3	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingWeightedAverageExercisePrice	0.00
CY2019Q3	obln	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	2000	USD
CY2019Q3	obln	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	9000	USD
	obln	Unpaid Stock Issuance Costs UnpaidStockIssuanceCosts	295000	USD
	obln	Unpaid Stock Issuance Costs UnpaidStockIssuanceCosts	0	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	648000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	656000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	285000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2019Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1300000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1310000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2326000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2531000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	188271000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	189353000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1105000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	536000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	659000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	470000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	292000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	259000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	45000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	70000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5328	shares
CY2019Q4	us-gaap	Assets Assets	20393000	USD
CY2020Q3	us-gaap	Assets Assets	11962000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	18235000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	9031000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	14055000	USD
CY2020Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	5514000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14055000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5500000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5514000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21187000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19380000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14055000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5514000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1807000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8541000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4825746	shares
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7724100	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7770698	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7724100	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7770698	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3706000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18763000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1560000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11009000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	424000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	61000	USD
CY2019Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	315000	USD
CY2020Q3	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	0	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	412000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2323000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	41000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1005000	USD
CY2019Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	361000	USD
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	260000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.07
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.42
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	820000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	116000	USD
CY2020Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	800000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2020Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	30000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	24000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	6000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-128000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	-79000	USD
	us-gaap	Gross Profit GrossProfit	171000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	3000	USD
	us-gaap	Gross Profit GrossProfit	522000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1200000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1257000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-724000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	8000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-632000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-285000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-69000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-363000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3097000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-688000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	117000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	524000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1604000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1389000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-363000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2107000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	9000	USD
CY2019Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	0	USD
CY2020Q3	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	3150000	USD
CY2020Q3	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	3150000	USD
CY2019Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	37000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-448000	USD
CY2020Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	29000	USD
	us-gaap	Interest Paid Net InterestPaidNet	700000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	89000	USD
CY2020Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	1936000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	0	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1835000	USD
CY2020Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12000	USD
CY2020Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020Q3	us-gaap	Inventory Write Down InventoryWriteDown	100000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	100000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	53000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1384000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	564000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	37000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	108000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	105000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	219000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	351000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	4544000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	6040000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20393000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11962000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3977000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5050000	USD
CY2020Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	7000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	567000	USD
CY2020Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	990000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	430000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13674000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	430000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2506000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-117000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17987000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8854000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-8290000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-6767000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-3706000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18763000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5261000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4188000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1560000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11009000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	3663000	USD
	us-gaap	Operating Expenses OperatingExpenses	18426000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	1562000	USD
	us-gaap	Operating Expenses OperatingExpenses	11149000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3742000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18255000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1559000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10627000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	400000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	600000	USD
CY2020Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	400000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1077000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	492000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	206000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1959000	USD
CY2020Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3517000	USD
CY2019Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	69000	USD
CY2020Q3	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	15000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1303000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1524000	USD
CY2020Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3634000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-60000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-411000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	117000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1890000	USD
CY2020Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	186000	USD
CY2020Q3	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	600000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8659000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	430000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	2550000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3407000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3513000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1081000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	982000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	20000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1174000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5401000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	271000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2293000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-172430000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-183439000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-183400000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	300000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	333000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2500000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2494000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1527000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1500000	USD
CY2019Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	107000	USD
CY2020Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	103000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2489000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13025000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1291000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7546000	USD
CY2019Q3	us-gaap	Share Based Compensation ShareBasedCompensation	659000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2300000	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	259000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1021000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	194831	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	790000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.49
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	125000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	504968	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1100137	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	39.42
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.97
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	7000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	279229	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	41.48
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	125000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1100137	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.97
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	37.74
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.79
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y8M19D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y11M12D
CY2019Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	24859	shares
CY2019Q3	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	3320	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	581000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8074000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14718000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	15849000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	5922000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13107000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6518000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8376000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20065000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15849000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11072000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7178000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5922000	USD
CY2019Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.10
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6061248	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3700538	shares
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7728639	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7727494	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font></div></div>

Files In Submission

Name	View Source	Status
0001427570-20-000062-index-headers.html	Edgar Link	pending
0001427570-20-000062-index.html	Edgar Link	pending
0001427570-20-000062.txt	Edgar Link	pending
0001427570-20-000062-xbrl.zip	Edgar Link	pending
a101amendedeip.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
obln-20200930.xml	Edgar Link	completed
obln-20200930.xsd	Edgar Link	pending
obln-20200930_cal.xml	Edgar Link	unprocessable
obln-20200930_def.xml	Edgar Link	unprocessable
obln-20200930_lab.xml	Edgar Link	unprocessable
obln-20200930_pre.xml	Edgar Link	unprocessable
obln-93020x10q.htm	Edgar Link	pending
oblnex311.htm	Edgar Link	pending
oblnex312.htm	Edgar Link	pending
oblnex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RSLS
ReShape Lifesciences Inc. Stock $rsls

2020 Q4 Form 10-Q Financial Statement

#000142757020000062 Filed on November 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS ReShape Lifesciences Inc. Stock $rsls

2020 Q4 Form 10-Q Financial Statement

#000142757020000062 Filed on November 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS
ReShape Lifesciences Inc. Stock $rsls